International Journal of Cardiology
Volume 76, Issue 2 , Pages 257-258 , November 2000

Myocardial infarction after aspirin cessation in stable coronary artery disease patients

  • Jean-Philippe Collet, MD

      Affiliations

    • Department of Cardiology, Centre Hospitalier Universitaire Pitié-Salpétrière, 47 Boulevard de l’Hôpital, 75013 Paris, France
    • Department of Cardiology, Centre Hospitalier Universitaire Bichat, Rue Huchard, 75018 Paris, France
    • Corresponding Author InformationCorresponding author. Tel.: +33-1-4217-6742; fax: +33-1-4217-6856
  • ,
  • Dominique Himbert, MD

      Affiliations

    • Department of Cardiology, Centre Hospitalier Universitaire Bichat, Rue Huchard, 75018 Paris, France
  • ,
  • Philippe G Steg, MD

      Affiliations

    • Department of Cardiology, Centre Hospitalier Universitaire Bichat, Rue Huchard, 75018 Paris, France

Received 29 June 2000 ,Accepted 13 September 2000.

References 

  1. Antiplatelet Trialist’s Collaboration Study . Collaborative overview of randomised trials of antiplatelets therapy. Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J. 1994;308:81–106
  2. Fitzgerald GA, Oates JA, Hawiger J, Maas RL, Roberts U, Lawson JA, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest. 1983;71:676–688
  3. Fitzgerald DJ, Roy L, Catella F. Platelet activation in unstable coronary disease. N Engl J Med. 1986;315:983–989
  4. Lam JYT, Latour JG, Lesperance J, Waters D. Platelet aggregation, coronary disease progression and future coronary events. Am J Cardiol. 1994;73:333–338
  5. Vial JH, McLeod LJ, Roberts MS. Rebound elevation in urinary thromboxane B2 and 6-keto-PFF1 alpha exacerbation alter aspirin withdrawal. Prostaglandin Thromboxane Leukot Res. 1991;21A:157–160

PII: S0167-5273(00)00399-5

International Journal of Cardiology
Volume 76, Issue 2 , Pages 257-258 , November 2000